Valuation: Virbac

Market Cap 3B 3.33B 2.77B 2.51B 4.74B 312B 4.86B 33.22B 13.24B 167B 12.49B 12.23B 532B P/E 2026 *
17.3x
P/E 2027 * 15.6x
Enterprise Value 3.11B 3.45B 2.87B 2.6B 4.91B 324B 5.03B 34.42B 13.72B 173B 12.95B 12.67B 551B EV / Sales 2026 *
2x
EV / Sales 2027 * 1.86x
Free-Float
49.03%
Yield 2026 *
0.47%
Yield 2027 * 0.53%
1 day+0.28%
1 week-0.14%
Current month+3.46%
1 month+13.25%
3 months+7.65%
6 months+3.91%
Current year+0.42%
1 week 347
Extreme 347
363
1 month 319.5
Extreme 319.5
366
Current year 297
Extreme 297
389.5
1 year 297
Extreme 297
389.5
3 years 249.7
Extreme 249.7
400
5 years 215
Extreme 215
446.5
10 years 102.1
Extreme 102.1
448.5
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Date Insider Type Main position Quantity % Market Cap. Importance
22/4/24 Sell

Chief Executive Officer

810 0.0096%
22/4/24 Sell

Chief Executive Officer

140 0.0017%
22/4/24 Sell

Chief Executive Officer

1,688 0.0200%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-0.14%+0.42%+32.72% 3.33B
+0.35%+1.36%+45.38%+140.47% 1,280B
-0.13%+1.48%+44.67%+90.43% 675B
+0.37%+0.05%+31.00%+112.84% 521B
+0.98%+3.37%+39.43%+69.59% 386B
-0.59%-2.11%+61.83%+45.16% 363B
+1.48%+0.33%+28.52%+59.02% 301B
+0.87%-0.31%+3.55%+36.59% 286B
+0.62%-2.17%+38.31%+75.12% 253B
-0.67%-2.72%+38.49%+123.56% 211B
Average +0.72%-0.52%+33.16%+78.55% 428B
Weighted average by Cap. +1.06%+0.20%+39.60%+97.28%

Financials

2026 *2027 *
Net sales 1.56B 1.73B 1.44B 1.3B 2.46B 162B 2.52B 17.22B 6.86B 86.67B 6.48B 6.34B 276B 1.65B 1.83B 1.53B 1.38B 2.61B 172B 2.67B 18.28B 7.29B 92.01B 6.87B 6.73B 293B
Net income 173M 192M 160M 145M 274M 18.02B 280M 1.92B 764M 9.65B 721M 706M 30.71B 193M 214M 178M 161M 305M 20.07B 312M 2.14B 851M 10.75B 803M 786M 34.21B
Net Debt 108M 120M 100M 90.41M 171M 11.26B 175M 1.2B 478M 6.03B 451M 441M 19.2B 64.2M 71.23M 59.31M 53.62M 101M 6.68B 104M 711M 283M 3.58B 267M 262M 11.39B
Projected Income Statement - Annual - Virbac
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change Volume
12/11/26 EUR 359.00 +0.28% 650
11/11/26 EUR 358.00 +0.14% 1,818
10/11/26 EUR 357.50 -0.14% 2,080
09/11/26 EUR 358.00 -0.42% 3,067
06/11/26 EUR 359.50 0.00% 3,366
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Virbac
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
358.00EUR
Average target price
412.29EUR
Spread / Average Target
+15.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Virbac
  1. Stock Market
  2. Stocks
  3. VIRP Stock